Merlin BioMed

Merlin BioMed

Merlin BioMed was a New York City based investment advisor which invested in biotechnology, pharmaceuticals, medical devices and healthcare sectors.

Merlin BioMed was a New York City based investment advisor. Founded in 1998 by Dr. Stuart T. Weisbrod, Merlin BioMed encompasses several hedge funds. Managed by healthcare professionals, they invest in biotechnology, pharmaceuticals, medical devices and healthcare sectors.

Investment

Merlin BioMed has made investments in CymaBay Therapeutics, Gemin X Pharmaceuticals, Calypso Medical, EUSA Pharma, RenaMed Biologics, GeneLabs Technologies, FibroGen, ARYx Therapeutics, Salient Surgical Technologies, ARIAD Pharmaceuticals, Ventaira Pharmaceuticals, Confluent Surgical, De Novo Pharmaceuticals, Skila and Health Hero Network.

They exited their investments in FibroGen, CymaBay Therapeutics, Salient Surgical Technologies, Gemin X Pharmaceuticals, ARYx Therapeutics, Calypso Medical, EUSA Pharma, ARIAD Pharmaceuticals, Genelabs Technologies, Confluent Surgical and Ventaira Pharmaceuticals.

Timeline

Funded Companies

Company
Industry
Website
Location
Gemin X Pharmaceuticals
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.